نتائج البحث

51

دورية أكاديمية

PMS17 - Secukinumab vs Adalimumab for The Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis At 48 Weeks from A Chilean Perspective.

المؤلفون: Rojas, R¹, Barbeau, M², Jugl, SM³, MacPherson, A⁴

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA937-A938. 1p.

النص الكامل

52

دورية أكاديمية

PMS38 - A Cost Per Responder Analysis of Secukinumab Vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Ankylosing Spondylitis at 52 Weeks from the Irish Payer Perspective.

المؤلفون: Gunda, P¹, Nikoglou, E², Jugl, SM³, Murphy, A⁴

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA533-A533. 1p.

النص الكامل

53

دورية أكاديمية

PMS16 - Secukinumab Shows Higher Symptomatic Improvement and Lower Cost Per Response vs. Adalimumab After One Year Treatment of Active Ankylosing Spondylitis: A Cost Per Responder Analysis from A Chilean Perspective.

المؤلفون: Rojas, R¹, Barbeau, M², Jugl, SM³, MacPherson, A⁴

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA937-A937. 1p.

النص الكامل

54

دورية أكاديمية

PMS28 - Budget Impact of Secukinumab For Ankylosing Spondylitis In The UK.

المؤلفون: Halliday, A¹, Hacking, V², Jugl, SM³, Gunda, P⁴, Nikoglou, E⁵, Miles, L⁶, Graham, CN⁷

المصدر: Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA535-A535. 1p.

النص الكامل

55

دورية أكاديمية

PMS3 - Secukinumab Provides Higher Symptomatic Improvement Versus Adalimumab in Psoriatic Arthritis: Comparative Effectiveness Up to 48 Weeks Assessed by two Matching-Adjusted indirect Comparisons.

المؤلفون: Thom, H¹, Hunger, M², Rosal, GF³, Gandhi, K⁴, Jugl, SM⁵, Nash, P⁶

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA935-A935. 1p.

النص الكامل

56

دورية أكاديمية

PSY39 - Delayed Biologic Switching Among Psoriatic Arthritis (Psa) Patients May Result in Poor Health-Related Quality of Life: Results From A Multi-National Survey Including Latin America.

المؤلفون: Ranza, R¹, Alten, R², Strand, V³, Sullivan, E⁴, Blackburn, S⁴, Tian, H⁵, Gandhi, K⁵, Jugl, SM⁶, Conaghan, PG⁷

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA903-A903. 1p.

النص الكامل

57

دورية أكاديمية

PSY40 - Delayed Biologic Switching Among Ankylosing Spondylitis (As) Patients May Result in Poor Health- Related Quality of Life: Results From A Multi-National Survey Including Latin America.

المؤلفون: Pereira, I¹, Alten, R², Conaghan, PG³, Strand, V⁴, Sullivan, E⁵, Blackburn, S⁵, Tian, H⁶, Gandhi, K⁶, Jugl, SM⁷, Deodhar, A⁸

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA903-A903. 1p.

النص الكامل

58

دورية أكاديمية

PMS31 - Comparison Ofsecukinumab Vs Adalimumab in a Cost Per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthrisis at 48 Weeks from a Moroccan Perspective.

المؤلفون: Kooli, A¹, Gunda, P², Toumi, J³, Nikoglou, E⁴, Jugl, SM⁵

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA531-A531. 1p.

النص الكامل

59

دورية أكاديمية

PMS54 - Cost-Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.

المؤلفون: Kirkham, B¹, Buchanan, V², Sullivan, W², Graham, CN³, Miles, L³, Jugl, SM⁴, Gunda, P⁵, Halliday, A⁶

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA536-A536. 1p.

النص الكامل

60

دورية أكاديمية

PMS50 - Secukinumab Vs. Adalimumab for Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis at 52 Weeks from an Argentinian Perspective.

المؤلفون: Barbeau, M¹, Bianculli, PM², Nikoglou, E³, Gunda, P⁴, Jugl, SM⁵, MacPherson, A⁶

المصدر: Value in Health. Oct2017, Vol. 20 Issue 9, pA535-A535. 1p.

النص الكامل

تنقيح النتائج